Cellular and Molecular Life Sciences

, Volume 68, Issue 4, pp 587–597 | Cite as

Aging and TOR: interwoven in the fabric of life



Longstanding results with calorie and growth factor restriction plus recent results with the first interventional drug suggest that retarding the pace of aging to improve the quality of life of older people is at hand. The biological system targeted by these approaches is the target of rapamycin (TOR), which is central for cellular responses to a variety of stimuli including stressors, growth factors, and nutrients and energy states. That the life-extending response to reducing its activity is highly conserved from yeast to mammals is consistent with the evolution of aging as a strategy to preserve reproductive potential of young cells and animals.


mTOR Rapamycin Healthy lifespan Growth factor restriction Caloric restriction 



Numerous discussions with the experts in aging research in the Institute of Biotechnology and Barshop Institute for Longevity and Aging Studies are gratefully acknowledged. I would also like to thank ITP investigators, Randy Strong, Rich Miller, David Harrison and Nancy Nadon for their knowledge and expertise in conducting aging studies, and for being wonderful colleagues in this ongoing adventure. Work in the author’s laboratory is supported by a Grand Opportunity grant from the NIH and by the Glenn Foundation. Finally, I would like to thank the anonymous reviewers for very helpful and insightful suggestions for improving the paper.


  1. 1.
    Lindner AB, Madden R, Demarez A, Stewart EJ, Taddei F (2008) Asymmetric segregation of protein aggregates is associated with cellular aging and rejuvenation. Proc Natl Acad Sci U S A 105:3076–3081PubMedGoogle Scholar
  2. 2.
    Maisonneuve E, Ezraty B, Dukan S (2008) Protein aggregates: an aging factor involved in cell death. J Bacteriol 190:6070–6075PubMedGoogle Scholar
  3. 3.
    Shapiro L, McAdams HH, Losick R (2002) Generating and exploiting polarity in bacteria. Science 298:1942–1946PubMedGoogle Scholar
  4. 4.
    Macara IG, Mili S (2008) Polarity and differential inheritance – universal attributes of life? Cell 135:801–812PubMedGoogle Scholar
  5. 5.
    Ackermann M, Stearns SC, Jenal U (2003) Senescence in a bacterium with asymmetric division. Science 300:1920PubMedGoogle Scholar
  6. 6.
    Erjavec N, Cvijovic M, Klipp E, Nyström T (2008) Selective benefits of damage partitioning in unicellular systems and its effects on aging. Proc Natl Acad Sci U S A 105:18764–18769PubMedGoogle Scholar
  7. 7.
    Egilmez NK, Jazwinski SM (1989) Evidence for the involvement of a cytoplasmic factor in the aging of the yeast Saccharomyces cerevisiae. J Bacteriol 171:37–42PubMedGoogle Scholar
  8. 8.
    Erjavec N, Nyström T (2007) Sir2p-dependent protein segregation gives rise to a superior reactive oxygen species management in the progeny of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 104:10877–10881PubMedGoogle Scholar
  9. 9.
    Aguilaniu H, Gustafsson L, Rigoulet M, Nystrom T (2003) Asymmetric inheritance of oxidatively damaged proteins during cytokinesis. Science 299:1751–1753PubMedGoogle Scholar
  10. 10.
    Reverter-Branchat G, Cabiscol E, Tamarit J, Ros J (2004) Oxidative damage to specific proteins in replicative and chronological-aged Saccharomyces cerevisiae. J Biol Chem 279:31983–31989PubMedGoogle Scholar
  11. 11.
    Liu B, Larsson L, Caballero A, Hao X, Öling D, Grantham J, Nyström T (2010) The polarisome is required for segregation and retrograde transport of protein aggregates. Cell 140:257–267PubMedGoogle Scholar
  12. 12.
    Sinclair DA, Guarente L (1997) Extrachromosomal rDNA circles – a cause of aging in yeast. Cell 91:1033–1042PubMedGoogle Scholar
  13. 13.
    Shcheprova Z, Baldi S, Frei SB, Gonnet G, Barral Y (2008) A mechanism for asymmetric segregation of age during yeast budding. Nature 454:728–734PubMedGoogle Scholar
  14. 14.
    Khmelinskii A, Keller PJ, Lorenz H, Schiebel E, Knop M (2010) Segregation of yeast nuclear pores. Nature 466:E1PubMedGoogle Scholar
  15. 15.
    Rujano MA, Bosveld F, Salomons FA, Dijk F, van Waarde MAWH, van der Want JJL, de Vos RAI, Brunt ER, Sibon OCM, Kampinga HH (2006) Polarised asymmetric inheritance of accumulated protein damage in higher eukaryotes. PLoS Biol 4:2325–2335Google Scholar
  16. 16.
    Hölldobler B, Wilson EO (2009) The superorganism: the beauty, elegance and strangeness of insect societies. W. W. Norton, New YorkGoogle Scholar
  17. 17.
    Uematsu K, Kutsukake M, Fukatsu T, Shimada M, Shibao H (2010) Altruistic colony defense by menopausal female insects. Curr Biol 20:1182–1186PubMedGoogle Scholar
  18. 18.
    Williams GC (1957) Pleiotropy, natural selection, and the evolution of senescence. Evolution 11:398–411Google Scholar
  19. 19.
    Sharp ZD, Strong R (2010) The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity. J Gerontol A Biol Sci Med Sci 65:580–589PubMedGoogle Scholar
  20. 20.
    Sarbassov DD, Ali SM, Sengupta S, Sheen J-H, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168PubMedGoogle Scholar
  21. 21.
    Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136:731–745PubMedGoogle Scholar
  22. 22.
    Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307–318PubMedGoogle Scholar
  23. 23.
    Salminen A, Kaarniranta K (2009) Regulation of the aging process by autophagy. Trends Mol Med 15:217–224PubMedGoogle Scholar
  24. 24.
    Laplante M, Sabatini DM (2009) An emerging role of mTOR in lipid biosynthesis. Curr Biol 19:R1046–R1052PubMedGoogle Scholar
  25. 25.
    Dowling RJO, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328:1172–1176PubMedGoogle Scholar
  26. 26.
    Blagosklonny MV (2010) Rapamycin and quasi-programmed aging: four years later. Cell Cycle 9:1859–1862PubMedGoogle Scholar
  27. 27.
    Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496–1501PubMedGoogle Scholar
  28. 28.
    Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL (2008) Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10:935–945PubMedGoogle Scholar
  29. 29.
    Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM (2010) Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290–303PubMedGoogle Scholar
  30. 30.
    Hasty P (2009) Rapamycin: the cure for all that ails. J Mol Cell Biol 2:17–19PubMedGoogle Scholar
  31. 31.
    Fontana L, Partridge L, Longo VD (2010) Extending healthy life span – from yeast to humans. Science 328:321–326PubMedGoogle Scholar
  32. 32.
    Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, Ouni I, Pierce N, Tang X, Lomenick B, Damoiseaux R, Hao R, del Moral PM, Verma R, Li Y, Li C, Houk KN, Jung ME, Zheng N, Huang L, Deshaies RJ, Kaiser P, Huang J (2010) Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotech 28:738–742Google Scholar
  33. 33.
    Powers RW 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S (2006) Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 20:174–184PubMedGoogle Scholar
  34. 34.
    Huber A, Bodenmiller B, Uotila A, Stahl M, Wanka S, Gerrits B, Aebersold R, Loewith R (2009) Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis. Genes Dev 23:1929–1943PubMedGoogle Scholar
  35. 35.
    Fabrizio P, Pozza F, Pletcher SD, Gendron CM, Longo VD (2001) Regulation of longevity and stress resistance by Sch9 in yeast. Science 292:288–290PubMedGoogle Scholar
  36. 36.
    Kennedy BK, Smith ED, Kaeberlein M (2005) The enigmatic role of Sir2 in aging. Cell 123:548–550PubMedGoogle Scholar
  37. 37.
    Kaeberlein M, Burtner CR, Kennedy BK (2007) Recent developments in yeast aging. PLoS Genet 3:e84PubMedGoogle Scholar
  38. 38.
    Kaeberlein M, Kennedy BK (2007) Protein translation. Aging Cell 6:731–734PubMedGoogle Scholar
  39. 39.
    Schieke SM, Finkel T (2007) TOR and aging: less is more. Cell Metab 5:233–235PubMedGoogle Scholar
  40. 40.
    Bonawitz ND, Shadel GS (2007) Rethinking the mitochondrial theory of aging: the role of mitochondrial gene expression in lifespan determination. Cell Cycle 6:1574–1578PubMedGoogle Scholar
  41. 41.
    Medvedik O, Lamming DW, Kim KD, Sinclair DA (2007) MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. PLoS Biol 5:e261PubMedGoogle Scholar
  42. 42.
    Johnson TE (2008) Caenorhabditis elegans 2007: the premier model for the study of aging. Exp Gerontol 43:1–4PubMedGoogle Scholar
  43. 43.
    Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F (2003) Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426:620PubMedGoogle Scholar
  44. 44.
    Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C (2008) A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet 4:e24PubMedGoogle Scholar
  45. 45.
    Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C (2007) Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell 6:95–110PubMedGoogle Scholar
  46. 46.
    Jia K, Chen D, Riddle DL (2004) The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 131:3897–3906PubMedGoogle Scholar
  47. 47.
    Sheaffer KL, Updike DL, Mango SE (2008) The target of rapamycin pathway antagonizes pha-4/FoxA to control development and aging. Curr Biol 18:1355–1364PubMedGoogle Scholar
  48. 48.
    Syntichaki P, Troulinaki K, Tavernarakis N (2007) eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature 445:922–926PubMedGoogle Scholar
  49. 49.
    Pan KZ, Palter JE, Rogers AN, Olsen A, Chen D, Lithgow GJ, Kapahi P (2007) Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell 6:111–119PubMedGoogle Scholar
  50. 50.
    Hamilton B, Dong Y, Shindo M, Liu W, Odell I, Ruvkun G, Lee SS (2005) A systematic RNAi screen for longevity genes in C. elegans. Genes Dev 19:1544–1555PubMedGoogle Scholar
  51. 51.
    Mair W, Dillin A (2008) Aging and survival: the genetics of life span extension by dietary restriction. Annu Rev Biochem 77:727–754PubMedGoogle Scholar
  52. 52.
    Yu H, Larsen PL (2001) DAF-16-dependent and independent expression targets of DAF-2 insulin receptor-like pathway in Caenorhabditis elegans include FKBPs. J Mol Biol 314:1017–1028PubMedGoogle Scholar
  53. 53.
    Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S (2004) Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 14:885–890PubMedGoogle Scholar
  54. 54.
    Zid BM, Rogers AN, Katewa SD, Vargas MA, Kolipinski MC, Lu TA, Benzer S, Kapahi P (2009) 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 139:149–160PubMedGoogle Scholar
  55. 55.
    Giannakou ME, Goss M, Partridge L (2008) Role of dFOXO in lifespan extension by dietary restriction in Drosophila melanogaster: not required, but its activity modulates the response. Aging Cell 7:187–198PubMedGoogle Scholar
  56. 56.
    Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L (2010) Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 11:35–46PubMedGoogle Scholar
  57. 57.
    Sharp ZD, Bartke A (2005) Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J Gerontol A Biol Sci Med Sci 60:293–300PubMedGoogle Scholar
  58. 58.
    Hsieh CC, Papaconstantinou J (2004) Akt/PKB and p38 MAPK signaling, translational initiation and longevity in Snell dwarf mouse livers. Mech Ageing Dev 125:785–798PubMedGoogle Scholar
  59. 59.
    Selman C, Tullet JMA, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson ICA, Schuster E, Batterham RL, Kozma SC, Thomas G, Carling D, Okkenhaug K, Thornton JM, Partridge L, Gems D, Withers DJ (2009) Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326:140–144PubMedGoogle Scholar
  60. 60.
    Masoro EJ (2005) Overview of caloric restriction and ageing. Mech Ageing Dev 126:913–922PubMedGoogle Scholar
  61. 61.
    Liang H, Masoro EJ, Nelson JF, Strong R, McMahan CA, Richardson A (2003) Genetic mouse models of extended lifespan. Exp Gerontol 38:1353–1364PubMedGoogle Scholar
  62. 62.
    Bartke A, Wright JC, Mattison JA, Ingram DK, Miller RA, Roth GS (2001) Extending the lifespan of long-lived mice. Nature 414:412PubMedGoogle Scholar
  63. 63.
    Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392–395PubMedGoogle Scholar
  64. 64.
    Miller RA, Strong R, Sharp ZD, Harrison DE, Nadon NL et al (in press) Rapamycin, but not resveratrol or simvastatin, extends lifespan of genetically heterogeneous mice. J GerontolGoogle Scholar
  65. 65.
    Suh Y, Atzmon G, Cho M-O, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P (2008) Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 105:3438–3442PubMedGoogle Scholar
  66. 66.
    Kuningas M, Magi R, Westendorp RG, Slagboom PE, Remm M, van Heemst D (2007) Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur J Hum Genet 15:294–301PubMedGoogle Scholar
  67. 67.
    Holloszy JO, Fontana L (2007) Caloric restriction in humans. Exp Gerontol 42:709–712PubMedGoogle Scholar
  68. 68.
    Redman LM, Heilbronn LK, Martin CK, Alfonso A, Smith SR, Ravussin E, Pennington CALERIE Team (2007) Effect of calorie restriction with or without exercise on body composition and fat distribution. J Clin Endocrinol Metab 92:865–872PubMedGoogle Scholar
  69. 69.
    Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO (2008) Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell 7:681–687PubMedGoogle Scholar
  70. 70.
    Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:201–204PubMedGoogle Scholar
  71. 71.
    Austad S (2010) Recent advances in vertebrate aging research 2009. Aging Cell 9:297–303PubMedGoogle Scholar
  72. 72.
    Tardif SD, Araujo A, Arruda MF, French JA, Sousa MB, Yamamoto ME (2008) Reproduction and aging in marmosets and tamarins. Interdiscip Top Gerontol 36:29–48PubMedGoogle Scholar
  73. 73.
    Korner A (1965) Growth hormone effects on RNA and protein synthesis in liver. J Cell Physiol 66(Suppl 1):153–162PubMedGoogle Scholar
  74. 74.
    van Buul-Offers S, Van den Brande JL (1982) Cellular growth in organs of dwarf mice during treatment with growth hormone, thyroxine and plasma fractions containing somatomedin activity. Acta Endocrinol (Copenh) 99:150–160Google Scholar
  75. 75.
    Bates PC, Holder AT (1988) The anabolic actions of growth hormone and thyroxine on protein metabolism in Snell dwarf and normal mice. J Endocrinol 119:31–41PubMedGoogle Scholar
  76. 76.
    Steffen KK, MacKay VL, Kerr EO, Tsuchiya M, Hu D, Fox LA, Dang N, Johnston ED, Oakes JA, Tchao BN, Pak DN, Fields S, Kennedy BK, Kaeberlein M (2008) Yeast life span extension by depletion of 60s ribosomal subunits is mediated by Gcn4. Cell 133:292–302PubMedGoogle Scholar
  77. 77.
    Mellet J (1973) Etude de l’effectif ribosomique du foie chez la souris normale et chez la souris naine. Biochimie 55:189–194PubMedGoogle Scholar
  78. 78.
    Cuervo AM (2008) Calorie restriction and aging: the ultimate “Cleansing Diet”. J Gerontol A Biol Sci Med Sci 63:547–549PubMedGoogle Scholar
  79. 79.
    Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PLoS ONE 5:e9979PubMedGoogle Scholar
  80. 80.
    Alvers AL, Fishwick LK, Wood MS, Hu D, Chung HS, Dunn WA Jr, Aris JP (2009) Autophagy and amino acid homeostasis are required for chronological longevity in Saccharomyces cerevisiae. Aging Cell 8:353–369PubMedGoogle Scholar
  81. 81.
    Hinnebusch AG (2005) Translational regulation of GCN4 and the general amino acid control of yeast. Annu Rev Microbiol 59:407–450PubMedGoogle Scholar
  82. 82.
    Cherkasova VA, Hinnebusch AG (2003) Translational control by TOR and TAP42 through dephosphorylation of eIF2alpha kinase GCN2. Genes Dev 17:859–872PubMedGoogle Scholar
  83. 83.
    Kubota H, Obata T, Ota K, Sasaki T, Ito T (2003) Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2 alpha kinase GCN2. J Biol Chem 278:20457–20460PubMedGoogle Scholar
  84. 84.
    Valenzuela L, Aranda C, Gonzalez A (2001) TOR modulates GCN4-dependent expression of genes turned on by nitrogen limitation. J Bacteriol 183:2331–2334PubMedGoogle Scholar
  85. 85.
    Zhao Y, Sohn JH, Warner JR (2003) Autoregulation in the biosynthesis of ribosomes. Mol Cell Biol 23:699–707PubMedGoogle Scholar
  86. 86.
    Miyoshi K, Tsujii R, Yoshida H, Maki Y, Wada A, Matsui Y, Toh EA, Mizuta K (2002) Normal assembly of 60S ribosomal subunits is required for the signaling in response to a secretory defect in Saccharomyces cerevisiae. J Biol Chem 277:18334–18339PubMedGoogle Scholar
  87. 87.
    Cristofalo VJ, Pignolo RJ (1993) Replicative senescence of human fibroblast-like cells in culture. Physiol Rev 73:617–638PubMedGoogle Scholar
  88. 88.
    Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16:1472–1487PubMedGoogle Scholar
  89. 89.
    Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253–262PubMedGoogle Scholar
  90. 90.
    Blagosklonny MV (2006) Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 5:2087–2102PubMedGoogle Scholar
  91. 91.
    Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS (2009) mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 5:279–289PubMedGoogle Scholar
  92. 92.
    Fogarty S, Hardie DG (2010) Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804:581–591PubMedGoogle Scholar
  93. 93.
    Tzatsos A, Kandror KV (2006) Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26:63–76PubMedGoogle Scholar
  94. 94.
    Dowling RJO, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin dependent translation initiation in breast cancer cells. Cancer Res 67:10804–10812PubMedGoogle Scholar
  95. 95.
    Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590PubMedGoogle Scholar
  96. 96.
    Kalender A, Selvaraj A, Kim SY, Gulati P, Br˚lÈ S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G (2010) Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner. Cell Metab 11:390–401PubMedGoogle Scholar
  97. 97.
    Dilman VM, Berstein LM, Zabezhinski MA, Alexandrov VA, Bobrov JF, Pliss GB (1978) Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Arch Geschwulstforsch 48:1–8PubMedGoogle Scholar
  98. 98.
    Dilman VM, Anisimov VN (1980) Effect of treatment with phenformin, diphenylhydantoin or l-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology 26:241–246PubMedGoogle Scholar
  99. 99.
    Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA (2010) Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9:188–197PubMedGoogle Scholar
  100. 100.
    Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, Semenchenko AV (2008) Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7:2769–2773PubMedGoogle Scholar
  101. 101.
    Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV (2010) Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 176:2092–2097PubMedGoogle Scholar
  102. 102.
    Blagosklonny MV, Campisi J (2008) Cancer and aging: more puzzles, more promises? Cell Cycle 7:2615–2618PubMedGoogle Scholar
  103. 103.
    Smith DL, Elam CF, Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB (2010) Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci 65A:468–474Google Scholar
  104. 104.
    Katewa SD, Kapahi P (2010) Dietary restriction and aging, 2009. Aging Cell 9:105–112PubMedGoogle Scholar
  105. 105.
    Higami Y, Yu BP, Shimokawa I, Bertrand H, Hubbard GB, Masoro EJ (1995) Anti-tumor action of dietary restriction is lesion-dependent in male Fischer 344 rats. J Gerontol A Biol Sci Med Sci 50:B72–B77PubMedGoogle Scholar
  106. 106.
    Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A (2003) Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci 58:B291–B296Google Scholar
  107. 107.
    Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O’Kane CJ, Rubinsztein DC (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15:433–442PubMedGoogle Scholar
  108. 108.
    Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ (2005) Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer’s disease brain. FEBS J 272:4211–4220PubMedGoogle Scholar
  109. 109.
    Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O’Kane CJ, Rubinsztein DC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36:585–595PubMedGoogle Scholar
  110. 110.
    Young DA, Nickerson-Nutter CL (2005) mTOR – beyond transplantation. Curr Opin Pharmacol 5:418–423PubMedGoogle Scholar
  111. 111.
    Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19–24PubMedGoogle Scholar
  112. 112.
    Tee AR, Blenis J (2005) mTOR, translational control and human disease. Semin Cell Dev Biol 16:29–37PubMedGoogle Scholar
  113. 113.
    Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mTOR, amyloid β and tau: effects on cognitive impairments. J Biol Chem 285:13107–13120PubMedGoogle Scholar
  114. 114.
    Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460:108–112PubMedGoogle Scholar
  115. 115.
    Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT (2009) Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 15:267–276PubMedGoogle Scholar
  116. 116.
    Mita MM, Mita A, Rowinsky EK (2003) The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2:S169–S177PubMedGoogle Scholar
  117. 117.
    Mita MM, Mita A, Rowinsky EK (2003) Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 4:126–137PubMedGoogle Scholar
  118. 118.
    Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM (2009) Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol 5:291–303PubMedGoogle Scholar
  119. 119.
    Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M (2009) The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 4:135–142PubMedGoogle Scholar
  120. 120.
    Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 17:1947–1954PubMedGoogle Scholar
  121. 121.
    Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24PubMedGoogle Scholar
  122. 122.
    Garber K (2009) Targeting mTOR: something old, something new. J Natl Cancer Inst 101:288–290PubMedGoogle Scholar
  123. 123.
    Abraham RT (2010) Lysosomal Rag-ulation of mTOR complex 1 activity. Cell Metab 11:341–342PubMedGoogle Scholar
  124. 124.
    Reiling JH, Sabatini DM (2006) Stress and mTORture signaling. Oncogene 25:6373–6383PubMedGoogle Scholar

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  1. 1.Department of Molecular Medicine, Institute of BiotechnologyUniversity of Texas Health Science Center San AntonioSan AntonioUSA

Personalised recommendations